Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 17, 2024

Primary Completion Date

January 10, 2027

Study Completion Date

July 10, 2028

Conditions
Breast Cancer
Interventions
DRUG

Continuation of CDK4/6 inhibitor Palbociclib

Continuation of CDK4/6 inhibitor Palbociclib

DRUG

Discontinuation of CDK4/6 inhibitor Palbociclib

Discontinuation of CDK4/6 inhibitor Palbociclib

DRUG

Continuation of CDK4/6 inhibitor -Palbociclib

Continuation of CDK4/6 inhibitor -Palbociclib

DRUG

Discontinuation of CDK4/6 inhibitor -Palbociclib

Discontinuation of CDK4/6 inhibitor -Palbociclib

DRUG

Continuation of CDK4/6 inhibitor Abemaciclib

Continuation of CDK4/6 inhibitor Abemaciclib

DRUG

Discontinuation of CDK4/6 inhibitor Abemaciclib

Discontinuation of CDK4/6 inhibitor Abemaciclib

Trial Locations (13)

59494

RECRUITING

Onkologiezentrum Soest-Iserlohn, Soest

78224

RECRUITING

Onkologisch-Gastroenterologische Schwerpunktpraxis Innere Medizin GbR, Singen

88212

RECRUITING

MVZ für Hämatologie und Onkologie, Ravensburg

Unknown

RECRUITING

Charité Berlin, Berlin

RECRUITING

Hämatologische Onkologische Praxis im Medicum, Bremen

ACTIVE_NOT_RECRUITING

St. Johannes Hospital Dortmund, Dortmund

ACTIVE_NOT_RECRUITING

Praxis und Tagesklinik, Friedrichshafen

RECRUITING

Hausärztliche und Onkologische Gemeinschaftspraxis, Gerlingen

ACTIVE_NOT_RECRUITING

Onkologische GP Gütersloh, Gütersloh

RECRUITING

Hämatologisch-Onkologische Praxis Altona, Hamburg

RECRUITING

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz

RECRUITING

MVZ für Hämatologie und Onkologie der MVZ Mülheim GmbH, Mülheim

RECRUITING

Krankenhaus Barmherzige Brüder Regensburg, Regensburg

All Listed Sponsors
lead

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

OTHER